Cluj-Napoca

• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadaci … Ended
  2024-512771-12-00 2 2024-09-17 Axial spondyloarthritis
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadaci … Ended
  2024-512773-27-00 2 2024-08-19 Rheumatoid arthritis, ulcerative colitis, atopic dermatitis, Crohn's d
• A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastati … Ended
  2023-506882-70-00 5 2024-08-16 Non-small-cell lung cancer
• Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended
  2023-508679-34-00 4 2024-07-30 Ulcerative Colitis
• A research study comparing how well different doses of the medicine NNC0487-0111 lower blood sugar in people with type 2 diabetes Ended
  2023-509412-28-00 4 2024-07-26 Type 2 Diabetes
• An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Lacosam … Ended
  2023-507991-32-00 2 2024-07-25 Epileptic seizures
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i … Ended
  2023-506696-10-00 5 2024-06-18 Non-Small Cell Lung Cancer
• RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHAR … Ended
  2023-510247-38-00 3 2024-06-07 Rheumatoid arthritis
• Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic … Ended
  2022-503009-39-00 3 2024-06-04 Subacute Cutaneous Lupus Erythematosus
• A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)- … Ended
  2023-506881-30-00 3 2024-05-15 Melanoma
• MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended
  2023-506425-12-00 5 2024-04-17 Uncontrolled and Resistant Hypertension
• Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7. Ended
  2022-501969-42-00 5 2024-03-28 Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criter
• An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Ivacaft … Ended
  2023-508115-23-00 2 2024-02-20 Cystic Fibrosis
• A study to test whether BI 685509 helps people with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liv … Ended
  2023-506083-13-00 4 2024-02-16 clinically significant portal hypertension (CSPH) in decompensated cir
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p … Ended
  2023-503333-22-00 5 2024-01-15 Moderate to severe controlled asthma according to Step 4 and Step 5 of
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the … Ended
  2023-503614-80-00 5 2023-12-14 Pulmonary Arterial Hypertension
• Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504673-20-00 4 2023-12-06 Ulcerative Colitis
• A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE Ended
  2022-502716-37-00 4 2023-11-27 Recurrent or advanced/metastatic solid tumors who are immunotherapy na
• Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended
  2022-502208-64-00 4 2023-11-25 Asthma
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight … Ended
  2022-502678-18-00 5 2023-11-07 Type 2 diabetes
• A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended
  2022-500777-14-00 4 2023-11-06 Atopic Dermatitis
• A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Ended
  2022-502476-23-00 4 2023-10-25 Treatment of immunotherapy-naive patients with previously untreated or
• Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended
  2022-502196-31-00 10 2023-08-21 Advanced or Recurrent Endometrial Cancer

Showing 385–408 of 473 trials